Hemab Therapeutics Holdings, Inc.

XNASHealth care

Last traded price · USD

$45.09

+4.62%Market closed

Delayed 15 minutes · Source: ViewTrade · 5 Nov 2026, 06:26 IST · A quote does not mean the product is available to trade on your account.

Day's open: $45.00
Previous close: $43.10
Volume: 499,702
Day's high: $45.14
Day's low: $41.96

In brief

Hemab Therapeutics Holdings, Inc. is a health care company listed on Nasdaq, valued at about $2.11B.
Its shares closed at $45.09 on 4 Nov 2026.
From India you can buy COAG in US dollars under the RBI's Liberalised Remittance Scheme, including a fraction of one share. See what it costs

Questions investors ask

Can I buy Hemab Therapeutics Holdings, Inc. (COAG) shares from India?

Yes. Indian residents can invest in the US stock market under the Reserve Bank of India's Liberalised Remittance Scheme (LRS), which lets a resident individual remit up to USD 250,000 per financial year, across all permitted purposes combined. US-listed stocks and ETFs are a permitted investment under the LRS. You are solely responsible for ensuring your remittances comply with the LRS annual limit, the applicable Tax Collected at Source (TCS) rules, and all reporting requirements, including Schedule FA in your income-tax return.

Do I need the price of a whole COAG share to invest?

Yes. You can buy fractional shares, which lets you invest a fixed rupee/dollar amount even in high-priced stocks. For example, if one share trades at USD 1,000 and you invest USD 100, you receive 0.1 of a share.

How much can I invest in US stocks in a year?

Under the LRS, an Indian resident can remit up to USD 250,000 per financial year (April to March) across all permitted purposes combined, from their own funds. This is a per-individual limit set by the RBI.

Can I trade COAG options or futures?

No. Under RBI / FEMA rules, the LRS does not permit margin trading or speculative instruments such as futures, options, or other derivatives. Your US account is a cash account, not a derivatives and margin account.

Insights

Quotes run fifteen minutes behind.

Behind SPY and its sector fund XLV over 3 months
1 month: +58.9% (SPY −1.6%, XLV +13.5%). 3 months: −10.0% (SPY −0.4%, XLV +15.5%). Price change to the 4 Nov 2026 close; dividends excluded.
Daily closes, split-adjusted: COAG, SPY and XLV · as of 4 Nov 2026
7.8 days to cover short interest
3.2M shares were sold short at the 15 Oct 2026 settlement; covering them would take 7.8 days of average volume. Short interest is reported twice a month, on a lag.
Exchange short-interest filing · as of 15 Oct 2026
Volume 2.2× its 30-session average on 29 Oct 2026
29 Oct 2026 volume of 1.2M shares was 2.2× the average of the 30 sessions before it (534.9K), as the price rose 5.0%. SPY traded 1.0× its own average that session.
Daily volume against a 30-session baseline · as of 29 Oct 2026
Above its 50-day average
The 4 Nov 2026 close of $45.09 was 20.0% above its 50-day average ($37.58).
Daily closes, split-adjusted; 50- and 200-session simple averages · as of 4 Nov 2026
RSI(14) at 73.1, 70 or above
The 14-session relative strength index closed at 73.1 on 4 Nov 2026, its 1st session at 70 or above. By convention a reading of 70 or above is called overbought and 30 or below oversold.
Daily closes, split-adjusted; Wilder's 14-session RSI · as of 4 Nov 2026

Returns

Price return, split-adjusted

At the 4 Nov 2026 close

1 month+58.9%

6 months+80.3%

1 year—

5 years—

Newswire

About

Hemab Therapeutics Holdings Inc is a clinical-stage biotechnology company developing therapies for the treatment of blood coagulation disorders. It focuses on discovering, developing, and commercializing treatments for conditions such as Glanzmann thrombasthenia, Factor VII deficiency, and von Willebrand disease. Its flagship candidate, sutacimig (HMB-001), is a bispecific antibody currently in clinical trials for the prophylactic treatment of Glanzmann thrombasthenia and Factor VII deficiency. The company has one operating segment, engaged in the research and development of prophylactic therapeutics for bleeding disorders.

Website

Notable moves

June 29, 2026
+13.47%
June 26, 2026
+16.77%
May 4, 2026
−25.47%

Newswire

About

Website

Notable moves

June 29, 2026
+13.47%
June 26, 2026
+16.77%
May 4, 2026
−25.47%

Hemab Therapeutics Holdings, Inc.

XNASHealth care

Last traded price · USD

$45.09

+4.62%Market closed

Delayed 15 minutes · Source: ViewTrade · 5 Nov 2026, 06:26 IST · A quote does not mean the product is available to trade on your account.

Day's open: $45.00
Previous close: $43.10
Volume: 499,702
Day's high: $45.14
Day's low: $41.96

In brief

Hemab Therapeutics Holdings, Inc. is a health care company listed on Nasdaq, valued at about $2.11B.
Its shares closed at $45.09 on 4 Nov 2026.
From India you can buy COAG in US dollars under the RBI's Liberalised Remittance Scheme, including a fraction of one share. See what it costs

Questions investors ask

Can I buy Hemab Therapeutics Holdings, Inc. (COAG) shares from India?

Do I need the price of a whole COAG share to invest?

How much can I invest in US stocks in a year?

Can I trade COAG options or futures?

Insights

Quotes run fifteen minutes behind.

Behind SPY and its sector fund XLV over 3 months
1 month: +58.9% (SPY −1.6%, XLV +13.5%). 3 months: −10.0% (SPY −0.4%, XLV +15.5%). Price change to the 4 Nov 2026 close; dividends excluded.
Daily closes, split-adjusted: COAG, SPY and XLV · as of 4 Nov 2026
7.8 days to cover short interest
3.2M shares were sold short at the 15 Oct 2026 settlement; covering them would take 7.8 days of average volume. Short interest is reported twice a month, on a lag.
Exchange short-interest filing · as of 15 Oct 2026
Volume 2.2× its 30-session average on 29 Oct 2026
29 Oct 2026 volume of 1.2M shares was 2.2× the average of the 30 sessions before it (534.9K), as the price rose 5.0%. SPY traded 1.0× its own average that session.
Daily volume against a 30-session baseline · as of 29 Oct 2026
Above its 50-day average
The 4 Nov 2026 close of $45.09 was 20.0% above its 50-day average ($37.58).
Daily closes, split-adjusted; 50- and 200-session simple averages · as of 4 Nov 2026
RSI(14) at 73.1, 70 or above
The 14-session relative strength index closed at 73.1 on 4 Nov 2026, its 1st session at 70 or above. By convention a reading of 70 or above is called overbought and 30 or below oversold.
Daily closes, split-adjusted; Wilder's 14-session RSI · as of 4 Nov 2026

Returns

Price return, split-adjusted

At the 4 Nov 2026 close

1 month+58.9%

6 months+80.3%

1 year—

5 years—

Newswire

About

Website

Notable moves

June 29, 2026
+13.47%
June 26, 2026
+16.77%
May 4, 2026
−25.47%

Newswire

About

Website

Notable moves

June 29, 2026
+13.47%
June 26, 2026
+16.77%
May 4, 2026
−25.47%

Hemab Therapeutics Holdings, Inc.

Hemab Therapeutics Holdings, Inc. in brief

Behind SPY and its sector fund XLV over 3 months

7.8 days to cover short interest

Volume 2.2× its 30-session average on 29 Oct 2026

Above its 50-day average

RSI(14) at 73.1, 70 or above

Hemab Therapeutics Holdings, Inc.

Hemab Therapeutics Holdings, Inc. in brief

Behind SPY and its sector fund XLV over 3 months

7.8 days to cover short interest

Volume 2.2× its 30-session average on 29 Oct 2026

Above its 50-day average

RSI(14) at 73.1, 70 or above